scholarly article | Q13442814 |
P50 | author | Eugene Braunwald | Q322114 |
Sabina A Murphy | Q114308442 | ||
Samuel C Volo | Q114358681 | ||
Benjamin M Scirica | Q114427115 | ||
Ewa Karwatowska-Prokopczuk | Q125171876 | ||
P2093 | author name string | David A Morrow | |
Luiz Belardinelli | |||
Bernard R Chaitman | |||
Jonathan W Waks | |||
Mei L Cheng | |||
P2860 | cites work | ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) | Q22242892 |
Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation | Q26995558 | ||
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties | Q34339876 | ||
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial | Q34578958 | ||
Atrial fibrillation and death after myocardial infarction: a community study | Q35125950 | ||
Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions | Q36485492 | ||
Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine | Q36507053 | ||
Role of late sodium channel current block in the management of atrial fibrillation | Q36570112 | ||
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial | Q37394525 | ||
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine | Q43196284 | ||
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation | Q44480000 | ||
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome | Q44805574 | ||
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial In | Q46048410 | ||
Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart | Q46082698 | ||
An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes | Q46725746 | ||
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death | Q50157358 | ||
P433 | issue | 1 | |
P921 | main subject | acute coronary syndrome | Q266018 |
Atrial Fibrillation | Q815819 | ||
P304 | page(s) | 32-37 | |
P577 | publication date | 2014-09-10 | |
P1433 | published in | EP Europace | Q2596718 |
P1476 | title | Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial | |
P478 | volume | 17 |
Q38770111 | A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome |
Q38853630 | Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation |
Q38297786 | Antiarrhythmic therapy in 2014: Contemporary approaches to treating arrhythmias |
Q26778659 | Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives |
Q47713126 | Ca2+/calmodulin-dependent kinase II-dependent regulation of atrial myocyte late Na+ current, Ca2+ cycling, and excitability: a mathematical modeling study |
Q38813373 | Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy |
Q36877207 | Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain |
Q38985149 | Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation |
Q38969897 | Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy. |
Q38420631 | Ranolazine for the treatment of atrial fibrillation |
Q26784029 | Ranolazine in Cardiac Arrhythmia |
Q39274533 | Ranolazine reduces atrial fibrillatory wave frequency |
Q55080711 | Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none? |
Q86038219 | Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries |
Q38821307 | The Significance of the Late Na+ Current for Arrhythmia Induction and the Therapeutic Antiarrhythmic Potential of Ranolazine |
Q48746789 | The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology |
Search more.